Dr. Mehta Discusses Combinations in Multiple Myeloma

Jayesh Mehta, MD
Published Online: Wednesday, Oct 25, 2017



Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.

In relapsed disease, it has been concluded that 3-drug regimens are better than 2-drug combinations. But, whether they are truly better in patients who may or may not undergo transplant is unclear, says Mehta.

This poses the question of giving more drugs upfront, or introducing drugs later in the disease course. Adding more drugs also brings up the question of cost.
 


Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.

In relapsed disease, it has been concluded that 3-drug regimens are better than 2-drug combinations. But, whether they are truly better in patients who may or may not undergo transplant is unclear, says Mehta.

This poses the question of giving more drugs upfront, or introducing drugs later in the disease course. Adding more drugs also brings up the question of cost.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Cancer Summaries and Commentaries™: Update from San Diego - Advances in the Treatment of Multiple MyelomaJan 31, 20181.5
Publication Bottom Border
Border Publication
x